{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:58:40Z","timestamp":1790985520595,"version":"4.1.0"},"reference-count":268,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105174","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:49:50Z","timestamp":1771573790000},"page":"105174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immunotherapy in triple-negative breast cancer: From molecular mechanisms to precision medicine\u2014overcoming resistance and optimizing clinical outcomes"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6833-3838","authenticated-orcid":false,"given":"Aniruddha","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shounak","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105174_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11912-021-01038-6","article-title":"Emerging therapeutics for patients with triple-negative breast cancer","volume":"23","author":"Agostinetto","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105174_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","article-title":"Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer","volume":"31","author":"Agostinetto","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105174_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14737140.2019.1631162","article-title":"Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy","volume":"19","author":"Aktas","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/pharmaceutics15010112","article-title":"Potential nanotechnology-based therapeutics to prevent cancer progression through TME cell-driven populations","volume":"15","author":"Ali","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105174_bib6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2174\/0113816128270102231016110637","article-title":"Efficacy and safety of atezolizumab monotherapy or combined therapy with chemotherapy in patients with metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Alimohammadi","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.critrevonc.2026.105174_bib7","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications from pathologist\u2019s perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib8","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1007\/s11033-021-06414-w","article-title":"Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis","volume":"48","author":"Arundhathi","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105174_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106427","article-title":"New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers","volume":"133","author":"Atta","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.critrevonc.2026.105174_bib10","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1304790110","article-title":"Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia","volume":"110","author":"Baginska","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib11","first-page":"75","article-title":"Immunotherapy for triple-negative breast cancer: a molecular insight into the microenvironment, treatment, and resistance","volume":"1","author":"Bai","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.critrevonc.2026.105174_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"Bairi","year":"2021","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib13","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3390\/ijms25063142","article-title":"Targeting the Warburg effect in cancer: where do we stand?","volume":"25","author":"Barba","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib14","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coi.2020.03.004","article-title":"Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy","volume":"64","author":"Barrett","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib16","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.3390\/cancers15153997","article-title":"Tumor mutational burden in breast cancer: current evidence, challenges, and opportunities","volume":"15","author":"Barroso-Sousa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2019.02.007","article-title":"Homologous recombination deficiency in triple negative breast cancer","volume":"45","author":"Belli","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105174_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s42234-025-00173-w","article-title":"Revolutionizing breast cancer immunotherapy by integrating AI and nanotechnology approaches: review of current applications and future directions","volume":"11","author":"Bendani","year":"2025","journal-title":"Bioelectron. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PAP.0000000000000382","article-title":"Role of surgical pathologist for detection of predictive immuno-oncological factors in breast cancer","volume":"30","author":"Berner","year":"2022","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-017-0627-0","article-title":"Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1","volume":"19","author":"Bertucci","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105174_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","article-title":"Next-generation cancer vaccines and emerging immunotherapy combinations","volume":"10","author":"Brandenburg","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib23","article-title":"CAR-T cell therapy for breast cancer: current status and future perspective","volume":"133","author":"Buono","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105174_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10549-018-4990-9","article-title":"Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set","volume":"173","author":"Cain","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105174_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1116016","article-title":"Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment","volume":"13","author":"Cao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12967-020-02219-w","article-title":"Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?","volume":"18","author":"Cetintas","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","article-title":"Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)","volume":"6","author":"Chae","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/jpm12020323","article-title":"Homologous recombination deficiency (HRD) and BRCA 1\/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): a systematic review and meta-analysis","volume":"12","author":"Chai","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104644","article-title":"Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases","volume":"93","author":"Chatziioannou","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105174_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers15010104","article-title":"Mechanisms and strategies to overcome PD-1\/PD-L1 blockade resistance in triple-negative breast cancer","volume":"15","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers15010104","article-title":"Mechanisms and strategies to overcome PD-1\/PD-L1 blockade resistance in triple-negative breast cancer","volume":"15","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1189\/jlb.5VMR1116-458RRR","article-title":"Myeloid-derived suppressor cells\u2014a new therapeutic target to overcome resistance to cancer immunotherapy","volume":"102","author":"Chesney","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/JIPO.JIPO_24_18","article-title":"Tackling immunotherapy resistance: developing rational combinations of immunotherapy and targeted drugs","volume":"2","author":"Cojocaru","year":"2019","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/1568009617666170927114440","article-title":"The PI3K Pathway at the crossroads of cancer and the immune system: strategies for next generation immunotherapy combinations","volume":"18","author":"Collins","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2026.105174_bib36","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC Class I Downregulation in Cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clbc.2023.06.004","article-title":"A review of AI-based radiomics and computational pathology approaches in triple-negative breast cancer: current applications and perspectives","volume":"23","author":"Corredor","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1186\/s12885-023-11293-4","article-title":"Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis","volume":"23","author":"Cortes","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105174_bib41","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahl\u00e9n","year":"2018","journal-title":"Ther. Adv. Vaccin. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105174_bib43","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"De La Cruz-L\u00f3pez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"De Ruiter","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib45","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies","volume":"389","author":"Denkert","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105174_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib47","article-title":"Advancements and hurdles in the development of a vaccine for triple-negative breast cancer: a comprehensive review of multi-omics and immunomics strategies","volume":"337","author":"Dhanushkumar","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC Class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2019.09.002","article-title":"Metabolic crosstalk in the breast cancer microenvironment","volume":"121","author":"Dias","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib50","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/cancers13061302","article-title":"Agonistic CD40 antibodies in cancer treatment","volume":"13","author":"Djureinovic","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/cancers11070904","article-title":"WNT signaling in cancer metabolism and immunity","volume":"11","author":"El-Sahli","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer","volume":"5","author":"Emens","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000510812","article-title":"Understanding PD-L1 testing in breast cancer: a practical approach","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care"},{"key":"10.1016\/j.critrevonc.2026.105174_bib55","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/vaccines8040776","article-title":"Neo-antigen mRNA vaccines","volume":"8","author":"Esprit","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2026.105174_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib57","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.3390\/cancers14225633","article-title":"Role of PARP inhibitors in cancer immunotherapy: potential friends to immune activating molecules and foes to immune checkpoints","volume":"14","author":"Franzese","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib59","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1186\/s12885-020-07654-y","article-title":"Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib60","article-title":"Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review","volume":"15","author":"Garc\u00eda","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14737159.2025.2482639","article-title":"Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care","volume":"25","author":"Gazzah","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2026.105174_bib62","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO1-28-10","article-title":"Abstract PO1-28-10: Tumor Infiltrating Lymphocytes identify patients with stage I TNBC with excellent outcome without chemotherapy","volume":"84","author":"Geurts","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib63","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-Infiltrating lymphocytes in patients with Stage I Triple-Negative Breast Cancer untreated with chemotherapy","volume":"10","author":"Geurts","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/CCO.0000000000000680","article-title":"Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results","volume":"32","author":"Goncalves","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40169-019-0225-x","article-title":"The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies","volume":"8","author":"Gong","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib68","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","article-title":"Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches","volume":"11","author":"Gupta","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105174_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00068","article-title":"Metabolic cooperation and competition in the tumor microenvironment: implications for therapy","volume":"7","author":"Gupta","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000455999","article-title":"Germline mutations in triple-negative breast cancer","volume":"12","author":"Hahnen","year":"2017","journal-title":"Breast Care"},{"key":"10.1016\/j.critrevonc.2026.105174_bib71","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-022-06547-x","article-title":"Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies","volume":"193","author":"Hall","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105174_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155651","article-title":"In silico analysis and comprehensive review of circular-RNA regulatory roles in breast diseases; a step-toward non-coding RNA precision","volume":"263","author":"Hamdy","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.critrevonc.2026.105174_bib74","article-title":"Insights into the genetic and epigenetic mechanisms governing X-chromosome-linked-miRNAs expression in cancer; a step-toward ncRNA precision","volume":"289","author":"Hamdy","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib75","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3390\/jcm8111989","article-title":"Targeting of the cancer-associated fibroblast\u2014T-cell axis in solid malignancies","volume":"8","author":"Harryvan","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029471","article-title":"Malignant giant cell tumor of toe","volume":"101","author":"Hashimoto","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.critrevonc.2026.105174_bib77","article-title":"Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target","volume":"78","author":"Hashemi","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib78","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12905-020-01038-x","article-title":"Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis","volume":"20","author":"He","year":"2020","journal-title":"BMC Women S Health"},{"key":"10.1016\/j.critrevonc.2026.105174_bib79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib80","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/pharmaceutics13101670","article-title":"Functionalized nanoparticles targeting tumor-associated macrophages as cancer therapy","volume":"13","author":"He","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105174_bib81","first-page":"88","article-title":"Classification of triple-negative breast cancers based on Immunogenomic profiling","volume":"39","author":"He","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2022.12.001","article-title":"Targeting lactate metabolism for cancer immunotherapy - a matter of precision","volume":"88","author":"Heuser","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib83","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/cancers12102969","article-title":"Cancer-associated fibroblasts: accomplices in the tumor immune evasion","volume":"12","author":"Hilmi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib84","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","article-title":"Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors","volume":"11","author":"Hou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1602452","article-title":"Role of TGF\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy","volume":"15","author":"Hou","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib86","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib87","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/2326-6066.CIR-24-1270","article-title":"Artificial intelligence can predict personalized immunotherapy outcomes in cancer","volume":"13","author":"Huang","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107726","article-title":"Gut microbiota reshapes the TNBC immune microenvironment: emerging immunotherapeutic strategies","volume":"215","author":"Huang","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1073797","article-title":"The potential of PARP inhibitors in targeted cancer therapy and immunotherapy","volume":"9","author":"Hunia","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib90","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clbc.2025.03.006","article-title":"Harnessing artificial intelligence for precision diagnosis and treatment of triple negative breast cancer","volume":"25","author":"Hussain","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib91","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib92","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semcancer.2019.12.026","article-title":"Roles of microbiota in response to cancer immunotherapy","volume":"65","author":"Inamura","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib93","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105174_bib94","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/ijms25021269","article-title":"Special issue \u201cMesenchymal Stromal Cells\u2019 involvement in human diseases and their treatment","volume":"25","author":"Jerkic","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71132","article-title":"Artificial intelligence-based pathology to assist prediction of neoadjuvant therapy responses for breast cancer","volume":"14","author":"Ji","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib97","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1186\/s12885-022-10284-1","article-title":"The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib98","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1007\/s00210-025-03896-4","article-title":"Tailored therapies for triple-negative breast cancer: current landscape and future perceptions","volume":"398","author":"Khan","year":"2025","journal-title":"Naunyn-Schmiede S Arch. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib99","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2026.105174_bib100","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/biomedicines10051130","article-title":"Immune checkpoint blockades in triple-negative breast cancer: current state and molecular mechanisms of resistance","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105174_bib101","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/cancers11111798","article-title":"Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117194","article-title":"Transforming the \u201ccold\u201d tumors to \u201chot\u201d tumors: strategies for immune activation","volume":"241","author":"Kong","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13062-025-00661-8","article-title":"Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review","volume":"20","author":"Krasniqi","year":"2025","journal-title":"Biol. Direct"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105174_bib104","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.22.00181","article-title":"Predicting response of Triple-Negative breast cancer to neoadjuvant chemotherapy using a deep convolutional neural Network\u2013Based artificial intelligence tool","author":"Krishnamurthy","year":"2023","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.critrevonc.2026.105174_bib105","doi-asserted-by":"crossref","first-page":"14403","DOI":"10.3390\/ijms241814403","article-title":"Exploring the complex and multifaceted interplay between melanoma cells and the tumor microenvironment","volume":"24","author":"Kuras","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib106","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","article-title":"Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials","volume":"7","author":"LaRocca","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib108","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14737140.2022.2023011","article-title":"Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis","volume":"22","author":"Latif","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105174_bib110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4081\/oncol.2019.425","article-title":"Efficacy and safety profiles of programmed cell death-1\/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review","volume":"13","author":"Lazarus","year":"2019","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105174_bib111","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib112","article-title":"Innate immune cells in tumor microenvironment: a new frontier in cancer immunotherapy","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105174_bib113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.21037\/cco.2017.08.04","article-title":"Rational combination of immunotherapy for triple negative breast cancer treatment","volume":"6","author":"Li","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib114","doi-asserted-by":"crossref","first-page":"9752","DOI":"10.1111\/jcmm.15539","article-title":"Nodakenin alleviated obstructive nephropathy through blunting Snail1 induced fibrosis","volume":"24","author":"Li","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib115","article-title":"Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754196","article-title":"Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib117","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"Npj Digit. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","article-title":"Immunotherapeutic interventions of triple negative breast cancer","volume":"16","author":"Li","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib119","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-022-01260-0","article-title":"Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies","volume":"15","author":"Liao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55185","article-title":"The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy","volume":"9","author":"Lim","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.critrevonc.2026.105174_bib121","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.7150\/thno.38425","article-title":"Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy","volume":"9","author":"Lim","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105174_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70403","article-title":"Decoding MHC loss: molecular mechanisms and implications for immune resistance in cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1393492","article-title":"Nanoparticle-enhanced PD-1\/PD-L1 targeted combination therapy for triple negative breast cancer","volume":"14","author":"Linde","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib124","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.7150\/ijbs.104079","article-title":"Revisiting of cancer immunotherapy: insight from the dialogue between glycolysis and PD-1\/PD-L1 axis in the tumor microenvironment","volume":"21","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib126","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1095839","article-title":"Triple negative breast cancer: immunogenicity, tumor microenvironment, and immunotherapy","volume":"13","author":"Loizides","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2026.105174_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1095839","article-title":"Triple negative breast cancer: immunogenicity, tumor microenvironment, and immunotherapy","volume":"13","author":"Loizides","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2026.105174_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118297","article-title":"PD-1\/PD-L1 axis importance and tumor microenvironment immune cells","volume":"259","author":"Lotfinejad","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib130","article-title":"Progress and prospect of immunotherapy for triple-negative breast cancer","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","article-title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment","volume":"11","author":"Ma","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.774103","article-title":"MTOR-mediated regulation of immune responses in cancer and tumor microenvironment","volume":"12","author":"Mafi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib133","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3390\/ijms23073871","article-title":"The interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy","volume":"23","author":"Maiorano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib134","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105174_bib135","doi-asserted-by":"crossref","first-page":"11256","DOI":"10.3390\/ijms252011256","article-title":"Cancer vaccines: recent insights and future directions","volume":"25","author":"Malacopol","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib136","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cncr.34084","article-title":"Regulatory T cells: their role in triple-negative breast cancer progression and metastasis","volume":"128","author":"Malla","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib137","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib138","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3389\/fimmu.2019.02854","article-title":"WNT signaling in Tumors: the way to evade drugs and immunity","volume":"10","author":"Martin-Orozco","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib139","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10238-024-01324-0","article-title":"Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients","volume":"24","author":"Mei","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib141","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12935-021-02107-3","article-title":"Triple-negative breast cancer: understanding Wnt signaling in drug resistance","volume":"21","author":"Merikhian","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2026.105174_bib142","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CCO.0000000000000878","article-title":"Immunotherapy and breast cancer: an overview","volume":"34","author":"Mezni","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib143","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imr.12978","article-title":"Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer","volume":"302","author":"Mhaidly","year":"2021","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105174_bib144","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clbc.2024.03.001","article-title":"The role of immunotherapy in triple-negative breast cancer (TNBC)","volume":"24","author":"Michaels","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib145","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib146","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/14737140.2023.2262764","article-title":"Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer","volume":"23","author":"Mohamed","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib147","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/pharmaceutics16060795","article-title":"Nano-delivery of immunogenic cell death inducers and immune checkpoint blockade agents: single-nanostructure strategies for enhancing Immunotherapy","volume":"16","author":"Moon","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105174_bib148","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/iub.1510","article-title":"Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes","volume":"68","author":"Mostafa","year":"2016","journal-title":"IUBMB Life"},{"key":"10.1016\/j.critrevonc.2026.105174_bib149","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.3390\/ijms24086945","article-title":"Therapeutic potential of tumor metabolic reprogramming in triple-negative breast cancer","volume":"24","author":"Munk\u00e1csy","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100536","article-title":"Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?","volume":"7","author":"Musacchio","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105174_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.598626","article-title":"Lactate metabolism and immune modulation in Breast Cancer: a focused review on triple negative breast tumors","volume":"10","author":"Naik","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib152","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: a review","volume":"234","author":"Najafi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib153","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS16-P6-10-03","article-title":"Abstract P6-10-03: KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)","volume":"77","author":"Nanda","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib154","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105174_bib155","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acsnano.2c01252","article-title":"Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs","volume":"16","author":"Nel","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105174_bib156","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"O\u2019Donnell","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib157","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14737140.2024.2341729","article-title":"Current usage of pembrolizumab in triple negative breast cancer (TNBC)","volume":"24","author":"O\u2019Rourke","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/diseases13010024","article-title":"Integrating AI into cancer immunotherapy\u2014a narrative review of current applications and future directions","volume":"13","author":"Olawade","year":"2025","journal-title":"Diseases"},{"key":"10.1016\/j.critrevonc.2026.105174_bib159","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","article-title":"The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality","volume":"67","author":"Papadimitriou","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105174_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680838","article-title":"Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer \u2013 a brief update","volume":"16","author":"Park","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000357","article-title":"How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies","volume":"3","author":"Park","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105174_bib162","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/cco.2017.02.04","article-title":"Next generation approaches for tumor vaccination","volume":"6","author":"Patel","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib163","doi-asserted-by":"crossref","first-page":"18274","DOI":"10.1039\/D4NR02795G","article-title":"Unleashing nanotechnology to redefine tumor-associated macrophage dynamics and non-coding RNA crosstalk in breast cancer","volume":"16","author":"Patni","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.critrevonc.2026.105174_bib164","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","article-title":"Homologous recombination repair deficiency and the immune response in breast cancer: a literature review","volume":"13","author":"Pellegrino","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib165","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","article-title":"Homologous recombination repair deficiency and the immune response in breast cancer: a literature review","volume":"13","author":"Pellegrino","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib166","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib167","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejca.2021.06.051","article-title":"Cancer and immunotherapy: a role for microbiota composition","volume":"155","author":"Pham","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib168","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.trecan.2021.05.004","article-title":"Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises","volume":"7","author":"Pham","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib169","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2017.12.008","article-title":"Checkpoint inhibitors in breast cancer \u2013 current status","volume":"63","author":"Polk","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105174_bib170","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/PO.20.00412","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","author":"Prince","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib171","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2147\/IJN.S285999","article-title":"Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors","volume":"16","author":"Qi","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.critrevonc.2026.105174_bib172","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib173","doi-asserted-by":"crossref","DOI":"10.1177\/11772719221078774","article-title":"Immune Checkpoint inhibitors in triple negative breast cancer: the search for the optimal biomarker","volume":"17","author":"Qureshi","year":"2022","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.critrevonc.2026.105174_bib174","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with Triple-Negative breast cancer","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib175","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non\u2013small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib176","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/imm.12675","article-title":"Antigen processing and immune regulation in the response to tumours","volume":"150","author":"Reeves","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105174_bib177","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib178","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2017.00248","article-title":"Metabolic hallmarks of tumor and immune cells in the tumor microenvironment","volume":"8","author":"Renner","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.903065","article-title":"Immunotherapy in triple-negative breast cancer: insights into tumor immune landscape and therapeutic opportunities","volume":"9","author":"Ribeiro","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.903065","article-title":"Immunotherapy in triple-negative breast cancer: insights into tumor immune landscape and therapeutic opportunities","volume":"9","author":"Ribeiro","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib181","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/biomedicines12020369","article-title":"Breaking barriers: the promise and challenges of immune checkpoint inhibitors in triple-negative breast cancer","volume":"12","author":"Said","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105174_bib182","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.14095","article-title":"Multi-omic analysis of dysregulated pathways in triple negative breast cancer","author":"Sajjad","year":"2024","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib183","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105174_bib184","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1200\/PO.20.00171","article-title":"Image-Guided Biopsy for Relapsed Neuroblastoma: focus on safety, adequacy for genetic sequencing, and correlation of tumor cell percent with quantitative lesion MIBG uptake","author":"Samoyedny","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib185","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib186","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib187","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1061789","article-title":"Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer","volume":"12","author":"Schreier","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib189","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00210-024-03308-z","article-title":"piR-823 tale as emerging cancer-hallmark molecular marker in different cancer types: a step-toward ncRNA-precision","volume":"398","author":"Shaker","year":"2024","journal-title":"Naunyn-Schmiede S Arch. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib191","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/biomedicines13092213","article-title":"Neoantigen-driven immunotherapy in triple-negative breast cancer: emerging strategies and clinical potential","volume":"13","author":"Shatalov","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105174_bib192","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib193","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner with T-Cell therapy for solid tumor treatment","volume":"9","author":"Shaw","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib194","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib195","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib196","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.3390\/ijms22136741","article-title":"MHC Class I deficiency in solid tumors and therapeutic strategies to overcome it","volume":"22","author":"Shklovskaya","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib197","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/pharmaceutics13020287","article-title":"Bio-Inspired and smart nanoparticles for triple negative breast cancer microenvironment","volume":"13","author":"Shokooh","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105174_bib198","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3390\/ijms22041964","article-title":"The MHC Class-I Transactivator NLRC5: implications to cancer immunology and Potential Applications to cancer immunotherapy","volume":"22","author":"Shukla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib199","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920909091","article-title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","volume":"12","author":"Simmons","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib200","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.drudis.2021.03.011","article-title":"The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer","volume":"26","author":"Singh","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105174_bib201","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/14712598.2021.1934446","article-title":"Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy","volume":"21","author":"Smith","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib202","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-023-01487-1","article-title":"Immunotherapy for early-stage triple negative breast cancer: is earlier better?","volume":"26","author":"Song","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105174_bib203","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.3390\/curroncol30040290","article-title":"Prognosis after local recurrence in patients with early-stage breast cancer treated without chemotherapy","volume":"30","author":"Sopik","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib204","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.3390\/cancers16193250","article-title":"Present and future of immunotherapy for triple-negative breast cancer","volume":"16","author":"Sriramulu","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105174_bib206","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib207","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3390\/cancers15082204","article-title":"Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type","volume":"15","author":"Subhan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib208","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib209","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/13543784.2021.1896702","article-title":"Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy","volume":"30","author":"Supabphol","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105174_bib210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1654748","article-title":"Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer","volume":"16","author":"Syeda","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib211","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/RLI.0000000000000518","article-title":"Impact of machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy and survival outcomes in breast cancer patients","volume":"54","author":"Tahmassebi","year":"2018","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib212","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib213","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/life15020283","article-title":"Towards the prediction of responses to Cancer Immunotherapy: a multi-omics review","volume":"15","author":"Tao","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2026.105174_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib216","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","article-title":"Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes","volume":"71","author":"Ting","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.critrevonc.2026.105174_bib217","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","article-title":"Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody\u2013drug conjugates and bispecific antibodies","volume":"191","author":"Torres","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105174_bib218","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The landscape of targeted therapies in TNBC","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib219","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/cancers15030767","article-title":"Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment","volume":"15","author":"Valenza","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib220","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review","volume":"24","author":"Van Den Ende","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib221","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1731942","article-title":"Lactate dehydrogenase: a marker of diminished antitumor immunity","volume":"9","author":"Van Wilpe","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105174_bib222","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cancers13092249","article-title":"Homologous recombination repair deficiency and implications for tumor immunogenicity","volume":"13","author":"Van Wilpe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib223","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5603","article-title":"ENGOT-OV43\/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer","volume":"37","author":"Vergote","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib224","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.816642","article-title":"Targeting PARP1 to enhance anticancer Checkpoint immunotherapy response: rationale and clinical implications","volume":"13","author":"Wanderley","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib226","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/cancers16173069","article-title":"TP53 Mutation-Mediated Immune Evasion in cancer: mechanisms and therapeutic implications","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105174_bib227","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.3390\/molecules27175607","article-title":"Lipid nanoparticles for mRNA delivery to enhance cancer immunotherapy","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2026.105174_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102435","article-title":"Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors","volume":"58","author":"Wang","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib229","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/jcm12030953","article-title":"Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges","volume":"12","author":"Wang","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105174_bib230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.canlet.2018.10.042","article-title":"Immunological therapy: a novel thriving area for triple-negative breast cancer treatment","volume":"442","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105174_bib231","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ctrv.2018.05.014","article-title":"Emerging therapeutic modalities of PARP inhibitors in breast cancer","volume":"68","author":"Wang","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105174_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105174_bib233","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of Immune checkpoint Blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105174_bib234","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12935-024-03261-0","article-title":"The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification","volume":"24","author":"Weng","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2026.105174_bib235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-023-07233-2","article-title":"High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy","volume":"205","author":"Wood","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105174_bib236","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105174_bib237","article-title":"Modulation of gut microbiota to enhance effect of checkpoint inhibitor immunotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib238","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217123","article-title":"The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: from association to cause and effect","volume":"598","author":"Xia","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105174_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105174_bib241","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1076883","article-title":"Advances in artificial intelligence to predict cancer immunotherapy efficacy","volume":"13","author":"Xie","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib242","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2020.07.044","article-title":"CAR T-cell therapy for triple-negative breast cancer: where we are","volume":"491","author":"Xie","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105174_bib243","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib244","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","article-title":"Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib245","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105174_bib246","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1471273","article-title":"Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes","volume":"15","author":"Yan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib247","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.copbio.2020.06.007","article-title":"Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy","volume":"66","author":"Yan","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib248","doi-asserted-by":"crossref","first-page":"A195.2","DOI":"10.1136\/jitc-2020-SITC2020.0318","article-title":"318\u2005Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and\/or homologous recombination repair deficiency: KEYLYNK-007","author":"Yap","year":"2020","journal-title":"Regul. Young Invest. Award Abstr."},{"key":"10.1016\/j.critrevonc.2026.105174_bib249","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105174_bib250","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/vaccines9070724","article-title":"Bispecific Antibodies: a smart arsenal for cancer immunotherapies","volume":"9","author":"You","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.critrevonc.2026.105174_bib251","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/life13051189","article-title":"Progress and challenges of immunotherapy predictive biomarkers for triple negative breast cancer in the era of single-cell multi-omics","volume":"13","author":"Yu","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2026.105174_bib252","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1206689","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib253","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202004397","article-title":"Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles","volume":"30","author":"Zeng","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.critrevonc.2026.105174_bib254","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011346","article-title":"Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105174_bib256","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/0284186X.2022.2106795","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis","volume":"61","author":"Zhang","year":"2022","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib257","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/life12121990","article-title":"Adverse events of PD-1 or PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2026.105174_bib258","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib259","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.3390\/ijms23137353","article-title":"Immunomodulatory properties of PI3K\/AKT\/MTOR and MAPK\/MEK\/ERK inhibition augment response to immune checkpoint blockade in melanoma and Triple-Negative breast cancer","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105174_bib260","article-title":"Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib261","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib262","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib263","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.accounts.0c00254","article-title":"Smart nanosized drug delivery systems inducing immunogenic cell death for combination with cancer immunotherapy","volume":"53","author":"Zhou","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.critrevonc.2026.105174_bib264","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","article-title":"Wnt signaling pathway in cancer immunotherapy","volume":"525","author":"Zhou","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105174_bib265","article-title":"Immunotherapy resistance in triple-negative breast cancer: molecular mechanisms, tumor microenvironment, and therapeutic implications","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib266","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.drudis.2020.07.006","article-title":"PD-1\/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer","volume":"25","author":"Zhu","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105174_bib267","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2018.00414","article-title":"Alteration of the antitumor immune response by Cancer-Associated fibroblasts","volume":"9","author":"Ziani","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105174_bib268","first-page":"517","article-title":"Research advances and new challenges in overcoming triple-negative breast cancer","volume":"4","author":"Zong","year":"2021","journal-title":"Cancer Drug Resist."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:57:18Z","timestamp":1775908638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":268,"alternative-id":["S1040842826000612"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105174","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in triple-negative breast cancer: From molecular mechanisms to precision medicine\u2014overcoming resistance and optimizing clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105174"}}